AVI CO 004

Drug Profile

AVI CO 004

Alternative Names: AVI-CO-004

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Avixgen
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 19 Dec 2016 Avixgen completes a phase I trial in HIV-1 infections (In volunteers) in South Korea (KCT0002005) prior to December 2016
  • 01 Aug 2016 Phase-I clinical trials in (In volunteers) HIV-1 infections in South Korea (unspecified route) (KCT0002005)
  • 31 Dec 2014 AVI CO 004 receives Orphan Drug status for HIV-1 infections in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top